A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

Phase 3 Completed 148 enrolled Astellas Pharma Europe B.V.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This was a 40-week study to investigate how safe and effective solifenacin solution was in treating children or adolescents with symptoms of overactive bladder (OAB), who completed study 905-CL-076 (NCT01565707).

Timeline

Start: 2012-10-04
Primary completion: 2014-10-08
Completion: 2014-10-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Solifenacin	Small molecule	—	Oral

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

Summary

Timeline

Drugs

Indications